Kim Seung Up, Han Kwang-Hyub, Nam Chung Mo, Park Jun Yong, Kim Do Young, Chon Chae Yoon, Ahn Sang Hoon
Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, South Korea.
J Gastroenterol Hepatol. 2008 Nov;23(11):1722-7. doi: 10.1111/j.1440-1746.2008.05510.x. Epub 2008 Aug 20.
Few studies have assessed the natural history of hepatitis B virus (HBV)-related cirrhotic ascites. We investigated the natural history of patients with HBV-related cirrhotic ascites hospitalized to control ascites and determined their prognosis, including survival rates and prognostic factors affecting survival.
Between January 1996 and December 2005, 203 consecutive patients with HBV-related cirrhotic ascites were followed for a median of 80.7 months (range, 15-149) after their first significant ascitic decompensation that required hospitalization.
The mean age of all patients was 52.6 years. Male gender predominated (male/female, 138/65). A subgroup analysis of 165 patients who had ascitic decompensation as their first episode of hepatic decompensation revealed that gastrointestinal variceal bleeding developed after a median interval of 8 months following ascitic decompensation in 31 (18.8%) patients, hepatic encephalopathy occurred at 9 months in 53 (32.1%), spontaneous bacterial peritonitis appeared at 12.7 months in 24 (14.5%), hepatorenal syndrome occurred at 8.1 months in five (3%), and hepatocellular carcinoma was observed at 21.2 months in 10 (6.1%). The overall median survival was 12.4 months. The 1- and 3-year survival rates were 50.7 and 18.7%. The prognostic factors that independently correlated with survival at the time of ascitic decompensation were Child-Pugh classification B/C (P = 0.030), serum white blood cell (WBC; P = 0.035), serum creatinine (Cr; P = 0.039), serum sodium (Na; P = 0.010), and antiviral therapy (P = 0.040).
The prognosis of HBV-related cirrhotic patients with ascitic decompensation is poor. Child-Pugh class, serum WBC/Cr/Na, and antiviral therapy primarily influenced survival.
很少有研究评估乙型肝炎病毒(HBV)相关肝硬化腹水的自然病史。我们调查了因腹水住院治疗的HBV相关肝硬化腹水患者的自然病史,并确定了他们的预后情况,包括生存率以及影响生存的预后因素。
在1996年1月至2005年12月期间,对203例连续性HBV相关肝硬化腹水患者进行随访,这些患者在首次因严重腹水失代偿而需住院治疗后,随访时间中位数为80.7个月(范围15 - 149个月)。
所有患者的平均年龄为52.6岁。男性占主导(男/女,138/65)。对165例以腹水失代偿作为首次肝脏失代偿发作的患者进行亚组分析发现,31例(18.8%)患者在腹水失代偿后中位间隔8个月出现胃肠道静脉曲张出血,53例(32.1%)在9个月时发生肝性脑病,24例(14.5%)在12.7个月时出现自发性细菌性腹膜炎,5例(3%)在8.1个月时发生肝肾综合征,10例(6.1%)在21.2个月时观察到肝细胞癌。总体生存中位数为12.4个月。1年和3年生存率分别为50.7%和18.7%。在腹水失代偿时与生存独立相关的预后因素为Child-Pugh分级B/C(P = 0.030)、血清白细胞(WBC;P = 0.035)、血清肌酐(Cr;P = 0.039)、血清钠(Na;P = 0.010)以及抗病毒治疗(P = 0.040)。
HBV相关肝硬化腹水失代偿患者的预后较差。Child-Pugh分级、血清WBC/Cr/Na以及抗病毒治疗对生存有主要影响。